Target intelligence / Profile preview

Mitogen-activated protein kinase kinase kinase 7 (MAP3K7)

Target
MAP3K7
Molecular classification
Enzyme, Kinase, Serine/threonine kinase
01

Overview

Mitogen-activated protein kinase kinase kinase 7 (MAP3K7), commonly known as transforming growth factor-beta-activated kinase 1 (TAK1), is a serine/threonine kinase that functions as a central signaling hub in eukaryotic cells. It integrates signals from various upstream stimuli, including TGF-beta, TNF-alpha, IL-1, and Toll-like receptor ligands, to activate downstream nuclear factor-kappa B (NF-kB) and mitogen-activated protein kinase (MAPK) pathways (such as JNK and p38). Through these pathways, MAP3K7 regulates critical cellular processes including cell survival, differentiation, inflammatory responses, and death.

Dysregulation of MAP3K7 is implicated in several human pathologies; its overexpression or hyperactivation promotes tumor growth, metastasis, and chemoresistance in various cancers, while its genetic loss or mutation is linked to developmental disorders like frontometaphyseal dysplasia type 2 and cardiospondylocarpofacial syndrome. Consequently, MAP3K7 has emerged as an attractive therapeutic target. Small-molecule inhibitors, such as takinib and EYD-001, are being developed to block its kinase activity, offering potential treatments for autoimmune diseases, chronic inflammation, and treatment-refractory cancers.

Other names
Transforming growth factor-beta-activated kinase 1TAK1MEKK7TGF1aCSCFFMD2
02

Mechanism of action

Inhibition of kinase activity, typically through ATP-competitive or irreversible binding, which blocks downstream NF-kB and MAPK signaling pathways.

03

Biological functions

Signal transductionApoptosisImmune responseCell deathCell survivalInflammation
04

Disease associations

CancerInflammationCardiovascular diseaseAutoimmune diseaseOther
05

Safety considerations

Hepatotoxicity and liver injury (conditional knockout in mice induces hepatocyte dysplasia and early-onset hepatocarcinogenesis)Systemic immunosuppression and increased susceptibility to infectionCardiotoxicity and dilated cardiomyopathy (loss-of-function variants are associated with dilated cardiomyopathy)Intestinal inflammation and tissue damageRedirection of TNF signaling to promote inflammatory cell death (TAK1 deficiency redirects combined TNF/IFN-gamma signaling to promote inflammatory cell death via RIPK1 and Caspase-8)
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Phosphorylated TAK1 (p-TAK1)MAP3K7 deletion/lossSF3B1 mutationDownstream cytokine levels (e.g., TNF-alpha, IL-6, MMP-3)

Beyond the preview

Go deeper on Mitogen-activated protein kinase kinase kinase 7 (MAP3K7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 7 (MAP3K7).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call